导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.07% | 3064/4773 |
| 近一周 | -0.46% | 198/5462 |
| 近一月 | 3.97% | 108/5421 |
| 近一季 | 3.46% | 360/5209 |
| 近半年 | -1.83% | 1702/4920 |
| 近一年 | 0.37% | 2585/4366 |
| 近两年 | 30.62% | 2246/2954 |
| 近三年 | 28.90% | 1097/2253 |
| 成立以来 | 199.88% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.60% 3654/4961 |
-9.26% 3949/5312 |
- - |
- - |
| 2025 | 10.02% 2839/4813 |
-2.08% 2839/3635 |
8.41% 336/4076 |
-3.36% 3988/4524 |
7.25% 308/4813 |
| 2024 | 31.59% 94/3463 |
8.62% 176/2808 |
4.45% 214/3014 |
15.07% 1821/3129 |
0.80% 1165/3463 |
| 2023 | 0.13% 422/2656 |
2.61% 1328/2280 |
1.66% 206/2385 |
4.14% 159/2515 |
-7.82% 2213/2655 |
| 2022 | -8.05% 152/2207 |
-2.64% 154/1919 |
-0.25% 1607/2016 |
-8.17% 174/2113 |
3.10% 769/2208 |
| 2021 | 6.09% 526/1822 |
5.56% 109/1255 |
-1.31% 1163/1330 |
1.96% 443/1466 |
-0.12% 1202/1822 |
| 2020 | 11.88% 818/1250 |
-10.63% 796/1028 |
3.59% 935/1067 |
12.33% 396/1164 |
7.58% 705/1184 |
| 2019 | 27.57% 541/1092 |
17.45% 657/754 |
1.90% 106/804 |
-1.44% 656/850 |
8.16% 346/918 |
| 2018 | -13.75% 90/834 |
- - |
- - |
- - |
-10.78% 225/691 |
| 2017 | 28.16% 80/714 |
- - |
- - |
- - |
- - |
| 2016 | -1.95% 123/605 |
- - |
- - |
- - |
- - |
| 2015 | 2.09% 240/575 |
- - |
- - |
- - |
- - |
| 2014 | 73.65% 12/237 |
- - |
- - |
- - |
- - |
| 2013 | -9.67% 149/186 |
- - |
- - |
- - |
- - |
| 2012 | 16.46% 8/140 |
- - |
- - |
- - |
- - |
| 2011 | -14.84% 6/102 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝上证180价值ETF VS. 长安沪深300非周期A(740101) |